These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 30755341)

  • 41. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
    Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
    JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
    Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
    Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
    Lane G; Risk M; Fan Y; Krishna S; Konety B
    BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer.
    McFerrin C; Davaro F; May A; Raza S; Siddiqui S; Hamilton Z
    Investig Clin Urol; 2020 Nov; 61(6):565-572. PubMed ID: 32985142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy.
    Chen J; Miranda G; Cai J; Daneshmand S; Djaladat H
    Scand J Urol; 2019; 53(2-3):123-128. PubMed ID: 31081431
    [No Abstract]   [Full Text] [Related]  

  • 46. Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
    Cha EK; Sfakianos JP; Sukhu R; Yee AM; Sjoberg DD; Bochner BH
    BJU Int; 2018 Oct; 122(4):627-632. PubMed ID: 29633530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer.
    D'Andrea D; Soria F; Zehetmayer S; Stangl-Kremser J; Grubmüller B; Abufaraj M; Gust K; Kimura S; Babjuk M; Goldner GM; Shariat SF
    Scand J Urol; 2020 Feb; 54(1):52-57. PubMed ID: 31975654
    [No Abstract]   [Full Text] [Related]  

  • 48. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
    Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant Versus Adjuvant Chemotherapy in Non-Metastatic Locally-Advanced Stage Radical Cystectomy Candidates.
    de Angelis M; Siech C; Jannello LMI; Bello FD; Peñaranda NR; Goyal JA; Touma N; Tian Z; Longo N; de Cobelli O; Chun FKH; Micali S; Saad F; Shariat SF; Gandaglia G; Moschini M; Montorsi F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2024 Oct; 22(5):102132. PubMed ID: 38972785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Which treatment is best for patients with AJCC stage IV bladder cancer?
    Mao W; Ma B; Huang X; Gu S; Luo M; Fan J; Geng J
    Int Urol Nephrol; 2019 Jul; 51(7):1145-1156. PubMed ID: 30949839
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.
    Zargar-Shoshtari K; Kongnyuy M; Sharma P; Fishman MN; Gilbert SM; Poch MA; Pow-Sang JM; Spiess PE; Zhang J; Sexton WJ
    World J Urol; 2016 Nov; 34(11):1567-1573. PubMed ID: 27072536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder.
    Kaushik D; Frank I; Boorjian SA; Cheville JC; Eisenberg MS; Thapa P; Tarrell RF; Thompson RH
    Int J Urol; 2015 Jun; 22(6):549-54. PubMed ID: 25761779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
    Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
    Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation.
    Gierth M; Fritsche HM; Buchner H; May M; Aziz A; Otto W; Bolenz C; Trojan L; Hermann E; Tiemann A; Müller SC; Ellinger J; Brookman-May S; Stief CG; Tilki D; Nuhn P; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Wieland WF; Riedmiller H; Denzinger S; Bastian PJ; Burger M
    World J Urol; 2014 Apr; 32(2):365-71. PubMed ID: 23736527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea.
    Kim SH; Seo HK; Shin HC; Chang SJ; Yun S; Joo J; Ku JH; Kim HS; Jeon HG; Jeong BC; Jeong IG; Kang SH; Hong B;
    J Korean Med Sci; 2015 Aug; 30(8):1150-6. PubMed ID: 26240494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.
    Matsumoto A; Nakagawa T; Kanatani A; Ikeda M; Kawai T; Miyakawa J; Taguchi S; Naito A; Otsuka M; Nakanishi Y; Suzuki M; Koga F; Nagase Y; Kondo Y; Okaneya T; Tanaka Y; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
    World J Urol; 2018 Feb; 36(2):249-256. PubMed ID: 29185045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study.
    Leveridge MJ; Siemens DR; Mackillop WJ; Peng Y; Tannock IF; Berman DM; Booth CM
    Urology; 2015 Apr; 85(4):791-8. PubMed ID: 25661830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.
    Fischer-Valuck BW; Rao YJ; Rudra S; Przybysz D; Germino E; Samson P; Baumann BC; Gay H; Michalski J
    J Urol; 2018 Feb; 199(2):416-423. PubMed ID: 28842247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.